BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Vigonvita Life Sciences readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Vigonvita Life Sciences's drugs r
 un\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06828887-841@assetmemo.bio
DTSTAMP:20261121T010138Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:LV232: Phase 2 readout est. (NCT06828887)
DESCRIPTION:LV232\, phase 2\, Major Depressive Disorder.\nStudy: Dose-Findi
 ng Clinical Trial to Evaluate the Efficacy and Safety of LV232 Capsules in
  the Treatment of MDD\nEstimated primary completion: 1 September 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/lv232#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06828887
URL:https://assetmemo.bio/drug/lv232#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07703956-9327@assetmemo.bio
DTSTAMP:20261121T010138Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:VV119: Phase 2 readout est. (NCT07703956)
DESCRIPTION:VV119\, phase 2\, Schizophrenia.\nStudy: Evaluating Safety and 
 Efficacy of VV119 in Acute Schizophrenia Adults\nEstimated primary complet
 ion: 31 October 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /vv119#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07703956
URL:https://assetmemo.bio/drug/vv119#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
